Adjuvant TACE combined with tislelizumab in patients with resected hepatocellular carcinoma at high risk of recurrence: An open-label, multicenter, phase II trial

被引：0
|
作者：
Ma, T. [1 ]
Wen, L. [1 ]
Zhang, J. [2 ]
Zhang, Z. [3 ]
Zeng, Y. [4 ]
Wang, Y. [5 ]
Zheng, J. [6 ]
Liang, T. [1 ]
机构：
[1] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Hepatobiliary & Pancreat Surg, Hangzhou, Peoples R China
[2] China Med Univ, Affiliated Hosp 1, Clin Med, Shenyang, Peoples R China
[3] Shandong Univ, Qilu Hosp, Dept Hepatobiliary Surg, Jinan, Peoples R China
[4] Fujian Med Univ, Mengchao Hepatobiliary Hosp, Dept Hepatobiliary & Pancreat Surg, Fuzhou, Peoples R China
[5] Tianjin Third Cent Hosp, Dept Hepatobiliary Surg, Tianjin, Peoples R China
[6] Hainan Gen Hosp, Dept Hepatobiliary & Pancreat Surg, Haikou, Hainan, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.10.259
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
239P
引用
收藏
页码：S1494 / S1494
页数：1
相关论文
共 50 条
  • [1] Adjuvant immunotherapy for resected esophageal squamous cell carcinoma with high risk of recurrence (AIRES): A multicenter, open-label, randomized, controlled phase III trial
    Kang, X.
    Xu, J.
    Zhang, R.
    Song, Y.
    Wang, Z.
    Zhang, B.
    Chen, X.
    Zheng, Q.
    Li, Y.
    Qin, J.
    Huang, J.
    Li, Y.
    He, J.
    ANNALS OF ONCOLOGY, 2021, 32 : S1072 - S1073
  • [2] Camrelizumab (C) in combination with apatinib (A) in patients with advanced hepatocellular carcinoma (RESCUE): An open-label, multicenter, phase II trial
    Xu, J.
    Shen, J.
    Gu, S.
    Zhang, Y.
    Wu, L.
    Wu, J.
    Shao, G.
    Zhang, Y.
    Xu, L.
    Yin, T.
    Liu, J.
    Ren, Z.
    Xiong, J.
    Mao, X.
    Zhang, L.
    Yang, J.
    Li, L.
    Chen, X.
    Wang, Z.
    Wang, Q.
    ANNALS OF ONCOLOGY, 2020, 31 : S689 - S689
  • [3] Tislelizumab in Patients with Previously Treated Advanced Hepatocellular Carcinoma (RATIONALE-208): A Multicenter, Non-Randomized, Open-Label, Phase 2 Trial
    Ren, Zhenggang
    Ducreux, Michel
    Abou-Alfa, Ghassan K.
    Merle, Philippe
    Fang, Weijia
    Edeline, Julien
    Li, Zhiwei
    Wu, Lihua
    Assenat, Eric
    Hu, Sheng
    Rimassa, Lorenza
    Zhang, Tao
    Blanc, Jean-Frederic
    Pan, Hongming
    Ross, Paul
    Yen, Chia-Jui
    Tran, Albert
    Shao, Guoliang
    Bouattour, Mohamed
    Chen, Yajin
    Meyer, Tim
    Hou, Jinlin
    Tougeron, David
    Bai, Yuxian
    Hou, Ming-Mo
    Meng, Zhiqiang
    Wu, John
    Li, Vincent
    Chica-Duque, Sandra
    Cheng, Ann-Lii
    LIVER CANCER, 2023, 12 (01) : 72 - 84
  • [4] Adjuvant tislelizumab plus TACE in resected high-risk hepatocellular carcinoma (ATTACK): Preliminary analysis of a prospective cohort study
    Liu, J.
    Zeng, D.
    Cheng, Y.
    Li, Y.
    Zhang, M.
    Song, S.
    Huang, Y.
    ANNALS OF ONCOLOGY, 2024, 35 : S1490 - S1490
  • [5] Randomized, open label, multicenter, phase II trial comparing transarterial chemoembolization (TACE) plus sorafenib with TACE alone in patients with hepatocellular carcinoma (HCC): TACTICS trial.
    Kudo, Masatoshi
    Ueshima, Kazuomi
    Ikeda, Masafumi
    Torimura, Takuji
    Tanabe, Nobukazu
    Aikata, Hiroshi
    Izumi, Namiki
    Yamasaki, Takahiro
    Nojiri, Shunsuke
    Hino, Keisuke
    Tsumura, Hidetaka
    Kuzuya, Teiji
    Isoda, Norio
    Yasui, Kohichiroh
    Yoshimura, Kenichi
    Okusaka, Takuji
    Furuse, Junji
    Kokudo, Norihiro
    Okita, Kiwamu
    Arai, Yasuaki
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [6] Ablation combined with tislelizumab in treating hepatocellular carcinoma: A phase II trial
    Xu, L.
    Ngai, S.
    Pan, Y.
    Zhang, Y.
    Chen, M-S.
    ANNALS OF ONCOLOGY, 2023, 34 : S1529 - S1529
  • [7] Tislelizumab plus donafenib combined with transarterial chemoembolization in patients with resected high-risk hepatocellular carcinoma (TIDE): A prospective, single-arm, phase II trial
    Peng, W.
    Hao, Y.
    Wei, Y.
    Xie, F.
    Li, C.
    Zhang, X.
    Shen, J.
    Lu, W.
    Zhou, J.
    Wen, T.
    ANNALS OF ONCOLOGY, 2024, 35 : S668 - S668
  • [8] TACE with dicycloplatin in patients with unresectable hepatocellular carcinoma: a multicenter randomized phase II trial
    Zhu, Hai-Dong
    Li, Xiao
    Ji, Jian-Song
    Huang, Ming
    Shao, Guo-Liang
    Lu, Jian
    Zhao, Xu-Ya
    Li, Hai-Liang
    Yang, Zheng-Qiang
    Tu, Jian-Fei
    Zhou, Jin-Mei
    Zeng, Chu-Hui
    Teng, Gao-Jun
    EUROPEAN RADIOLOGY, 2022, 32 (11) : 7335 - 7343
  • [9] TACE with dicycloplatin in patients with unresectable hepatocellular carcinoma: a multicenter randomized phase II trial
    Hai-Dong Zhu
    Xiao Li
    Jian-Song Ji
    Ming Huang
    Guo-Liang Shao
    Jian Lu
    Xu-Ya Zhao
    Hai-Liang Li
    Zheng-Qiang Yang
    Jian-Fei Tu
    Jin-Mei Zhou
    Chu-Hui Zeng
    Gao-Jun Teng
    European Radiology, 2022, 32 : 7335 - 7343
  • [10] Randomized, open label, multicenter, phase II trial of transcatheter arterial chemoembolization (TACE) therapy in combination with sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial.
    Kudo, Masatoshi
    Ueshima, Kazuomi
    Torimura, Takuji
    Tanabe, Nobukazu
    Ikeda, Masafumi
    Aikata, Hiroshi
    Izumi, Namiki
    Yamasaki, Takahiro
    Nojiri, Shunsuke
    Hino, Keisuke
    Tsumura, Hidetaka
    Isoda, Norio
    Yasui, Kohichiroh
    Kuzuya, Teiji
    Okusaka, Takuji
    Furuse, Junji
    Kokudo, Norihiro
    Okita, Kiwamu
    Yoshimura, Kenichi
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345